Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion

DMARD
biological therapy
golimumab
tnf blocker
certolizumab pegol
  • 17 views
  • 02 Aug, 2021
  • 35 locations
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade

algorithm; in this group the Tumor Necrosis Factor inhibitor (TNFi) golimumab will be utilised (the "TNFi Induction"-strategy). To define the window of opportunity within which temporary treatment

  • 0 views
  • 24 Feb, 2021
  • 6 locations
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate efficacy of golimumab in inducing clinical remission as assessed by the Mayo score, in pediatric participants with moderately to severely active

infliximab
azathioprine
mercaptopurine
endoscopy
remission
  • 53 views
  • 17 Jul, 2021
  • 87 locations
GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA)

An investigator-initiated double-blind, parallel-group randomised controlled trial of GOLimumab and Methotrexate versus Methotrexate in very early PsA using clinical and whole body MRI outcomes

  • 0 views
  • 23 Jan, 2021
  • 1 location
Golimumab for the Treatment of Refractory Behcet's Uveitis

The aim of this single-center prospective study is to evaluate the efficacy and safety of Golimumab GOL, fully humanized anti-tumor necrosis factor (TNF)- monoclonal antibody, in the treatment

immunosuppressive agents
prednisolone acetate ophthalmic suspension
immunosuppressant
monoclonal antibodies
behcet's syndrome
  • 1 views
  • 21 Mar, 2021
  • 1 location
Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

The purpose of this study is to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete

hemoglobin a1c
liraglutide
diabetes
golimumab
fasting
  • 93 views
  • 01 Aug, 2021
  • 2 locations
Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization

It is planned to enroll 80 UC patients who will require optimization of golimumab after secondary LOR. The review of the study protocol and its approval by an Independent Ethics Committee of the

golimumab
endoscopy
  • 6 views
  • 27 Jan, 2021
  • 5 locations
Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease

Prospective, multicentre trial which the biologic treatment will be initiated by clinical indication. The treatment selection anti-TNF (infliximab, adalimumab or golimumab), vedolizumab and

immunosuppressive agents
infliximab
luminal
tumor necrosis factor alpha
vedolizumab
  • 32 views
  • 24 Jan, 2021
  • 16 locations
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis

infliximab, adalimumab and golimumab) revolutionized the management of immune-mediated chronic diseases in the past two decades. However, about one third of patients will not respond to a first anti

proctocolectomy
janus kinase inhibitor
tumour necrosis
vedolizumab
remission
  • 2 views
  • 26 Jan, 2021
  • 24 locations
Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients

starting on a new biologic agent (infliximab, adalimumab, golimumab, vedolizumab). The overall objective is to (1) evaluate the efficacy, safety and tolerability of phentermine-topiramate, and (2

  • 0 views
  • 05 Feb, 2021
  • 1 location